Formulary tier placement for commonly prescribed branded drugs: Benchmarking and creation of a preferred placement index

American Journal of Managed Care

Volumn 13, Issue 6 II, 2007, Pages 377-384

  Mullins, C Daniel ^a   Palumbo, Francis B ^a   Saba, Mojdeh ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; ATORVASTATIN; AZITHROMYCIN; CARDIOVASCULAR AGENT; CARVEDILOL; CEFDINIR; ETHINYLESTRADIOL PLUS NORELGESTROMIN; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LAMOTRIGINE; METOPROLOL SUCCINATE; OLOPATADINE; QUETIAPINE; RALOXIFENE; RISEDRONIC ACID; RISPERIDONE; ROSIGLITAZONE; SERTRALINE; SIMVASTATIN; SUMATRIPTAN SUCCINATE; UNINDEXED DRUG; VALACICLOVIR; VALPROATE SEMISODIUM; VALSARTAN; VENLAFAXINE;

ARTICLE; COST CONTROL; DRUG CHOICE; DRUG COST; DRUG FORMULARY; HEALTH INSURANCE; MEDICAID; PRESCRIPTION; PRIORITY JOURNAL;

BENCHMARKING; COST SHARING; CROSS-SECTIONAL STUDIES; DEDUCTIBLES AND COINSURANCE; DRUG THERAPY; FORMULARIES; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; PRESCRIPTION FEES; UNITED STATES;

EID: 34250903035     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Mullins CD, Wang J, Palumbo FB, Stuart B. The impact of pipeline drugs on drug spending growth. Health Aff (Millwood). 2001;20:210-215.
2. Kennedy J, Coyne J, Sclar D. Drug affordability and prescription noncompliance in the United States: 1997-2002. Clin Ther. 2004;26: 607-614.
3. AARP Public Policy Institute. Trends in manufacturer prices of brand name prescription drugs used by older Americans: 2005 year-end update. Available at: http://assets.aarp.org/rgcenter/health/dd134_ drugprices.pdf. Accessed February 3, 2007.
4. Joyce GF, Escarse JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288: 1733-1739.
5. Pearson SA, Ross-Degnan D, Payson A, Soumerai SB. Changing medication use in managed care: a critical review of the available evidence. Am J Manag Care. 2003;9:715-731.
6. Levit K, Smith C, Cowan C, Lazenby H, Martin A. Inflation spurs health spending in 2000. Health Aff (Millwood). 2002;21:172-181.
7. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39: 1293-3104.
8. Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther. 2003;25:3147-3161.
9. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
10. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;19:2344-2350.
11. Shrank WH, Young HN, Ettner SL, Glassman P, Asch SM, Kravitz RL. Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? results from a physician leadership survey. Am J Manag Care. 2005;11:16-22.
12. Shihy C, Sleath BL. Health care provider knowledge of drug formulary status in ambulatory care settings. Am J Health Syst Pharm. 2004;61:2657-2663.
13. RxList Inc. The top 300 prescriptions for 2004 by number of US prescriptions dispensed. 2004. Available at: http://www.rxlist.com/script/main/ art.asp?articlekey=76774. Accessed April 13, 2007.
14. Center for Drug Evaluation and Research. Electronic Orange Book: approved drug products with therapeutic equivalence evaluations. December 2006. Available at: http://www.fda.gov/cder/ob/default.htm. Accessed February 2, 2007.
15. National Association of Chain Drug Stores. Industry facts at-a-glance. 2005. Available at: http://www.nacds.org/wmspage.cfm? parm1=507. Accessed July 7, 2005.
16. Shrank WH, Ettner SL, Glassman P, Asch SM. A bitter pill: formulary variability and the challenge to prescribing physicians. J Am Board Fam Pract. 2004;17:401-407.
17. Motheral BR, Heinle SM. Predictors of satisfaction of health plan members with prescription drug benefits. Am J Health Syst Pharm. 2004;61:1007-1014.
18. Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The health effects of restricting prescription medication use because of cost. Med Care. 2004;42:626-634.
19. Kaiser Family Foundation. Employer Health Benefits 2005 Annual Survey. Available at: http://www.kff.org/insurance/7315/sections/ehbs05-9-1.cfm. Accessed December 7, 2006.